Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2015

View Archived Issues

Astellas Pharma presents milestones of fourth quarter of fiscal 2014

Sun Biomedical agrees to acquire Dimerix Bioscience

Eisai patents FGFR-4 inhibitors

Angion Biomedica plans phase III trial of BB3 in delayed kidney graft function

Tonix Pharmaceuticals starts phase III trial of TNX-102 SL for fibromyalgia

Dicerna expands phase I trial of DCR-MYC to include PNET cohort

Discovery Labs' phase IIa study of Aerosurf meets key objectives

Luye Pharma completes three studies for risperidone extended-release microspheres

FDA grants fast track designation to TRC-105 for renal cell carcinoma

Xadago launched in Germany for mid- to late-stage Parkinson's disease

ISIS-664844 selectively targets the P23H variant of Rhodopsin

Vaccination with FSPs shows potential for the treatment of MSI-H CRC

FDA approves Treximet for use in pediatric migraine

Novartis reports development of complement factor B inhibitors

FORUM Pharmaceuticals patents nAChR alpha7 agonists

Chugai discloses DDR1 inhibitors

Taisho develops antibacterial hydroxamic acids

Boehringer Ingelheim exercises option for Pharmaxis drug candidate

Preliminary phase I trial results presented on DC vaccination therapy for AML

Selecta and Genethon to investigate technology enabling repeat dosing of gene therapies

Alnylam files for permission to start phase I/II trial of alpha1-antitrypsin RNAi therapeutic

Mitsubishi Tanabe files application in Japan for Remicade in Kawasaki disease

Sacituzumab govitecan awarded FDA fast track designation for NSCLC

Bristol-Myers Squibb's IPN-007 receives U.S. orphan status for progressive supranuclear palsy

Prostanoid EP2/3 agonist ONO-8055: a promising agent for underactive bladder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...